According to Palo Alto, California-based Atropos, its researchers have already come up with an initial AI model that has ...

Synthetic data is emerging as a powerful solution to the ongoing challenge of balancing patient privacy with the need for ...

Washington DC-based Vanda was sent a complete response letter (CRL) from the FDA in 2019, rejecting Hetlioz (tasimelteon) for ...

Guaranteed domain ownership: The first to pre-register a specific .med domain will be guaranteed to secure it at launch. Go ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...

At ASCO 2025, Bayer announced new data from recent clinical trials that highlight significant advancements in both prostate ...

Skyhawk recently started dosing patients in its phase 2/3 FALCON-HD trial of lead candidate SKY-0515, involving patients with ...

The convergence of behavioural health and movement disorder assessment technologies represents just the beginning of a ...

Along with plenty of initiatives in areas like food and exposure to chemicals like pesticides, the document (PDF), acquired ...

Tonmya – a new under-the-tongue formulation of well-established muscle relaxant cyclobenzaprine HCl – has been cleared to ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...